Contact: Amy Simmons Farber 202 309 0338
We are encouraged that the Department of Health and Human Services General Counsel publicly issued a letter that raises concerns about Eli Lilly’s 340B pricing refusals. As we have noted in the past, the drug manufacturer’s actions will have a devastating impact on Community Health Centers and the nearly 30 million patients they serve. While the HHS letter stands as a significant rebuke to Eli Lilly for seeking to boost their profits on the backs of millions of low-income health center patients, we do not believe we are out of the woods. Our position, and that of many Members of Congress, is that such actions are unlawful.
The community of community health centers will continue to voice their opposition about Eli Lilly’s actions and that of other drugmakers who choose profits over patients, particularly at a time when health centers are struggling to keep their doors open while serving on the front lines of the COVID pandemic.
###
Established in 1971, the National Association of Community Health Centers (NACHC) serves as the national voice for America’s Health Centers and as an advocate for health care access for the medically underserved and uninsured.